Plain-English translation of NCT04493164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications—CPX-351 and —work better together to treat a type of blood cancer called acute myeloid leukemia (AML) or a related condition called high-risk myelodysplastic syndrome (MDS). Both conditions affect how blood cells develop. The trial focuses on patients whose cancer has a specific genetic change called an IDH1 mutation. Researchers want to see if this medication combination can help patients go into remission and stay healthy longer.
Many patients with this type of blood cancer have limited treatment options, especially if their cancer has returned after previous treatment or did not respond to it. The study aims to find out whether combining these two medications—each of which targets the cancer in different ways—might be more effective than using them separately or other current treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive treatment in three phases over approximately 2 years. During the initial phase, you'll receive one medication through an IV infusion on specific days each week and take a daily pill at home. If your cancer responds well, you'll move to a second phase with similar treatment but fewer infusions. Finally, you'll enter a maintenance phase where you take the daily pill for up to 2 years. Throughout the trial, you'll have regular blood tests and doctor visits to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States